Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25948635 | 0.86 | MAP4K1 (0.46) | MAP4K1MAPK14 | |
| SCHEMBL21703436 | 0.86 | MAP4K1 (0.41) | MAP4K1MAPK14TLR7 | |
| SCHEMBL21703079 | 0.85 | MAP4K1 (0.42) | MAP4K1BRD4 | |
| SCHEMBL21703333 | 0.85 | MAP4K1 (0.43) | MAP4K1MAPK14CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL21703359 | 0.82 | MAP4K1 (0.49) | MAP4K1MAPK14CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL21684626 | 0.80 | MAP4K1 (0.35) | MAP4K1TLR7 | |
| SCHEMBL21703080 | 0.80 | MAP4K1 (0.42) | MAP4K1 | |
| SCHEMBL25948643 | 0.79 | MAP4K1 (0.46) | MAP4K1MAPK14 | |
| SCHEMBL21703004 | 0.77 | DHFR (0.44) | MAP4K1MAPK14 | |
| SCHEMBL25945082 | 0.75 | MAP4K1 (0.51) | MAP4K1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | MAP4K1 2520/4885MAPK14 3990/4885CYP1A1 4408/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | MAP4K1 2520/4885MAPK14 3990/4885CYP1A1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.